Masimo Celebrates Multiple Wins at the iF DESIGN AWARDS 2024

Rhea-AI Summary

Masimo (NASDAQ: MASI) and Bowers & Wilkins received six prestigious accolades at the iF DESIGN AWARDS 2024, showcasing their commitment to design excellence and innovation. With 11,000 submissions from 72 countries, Masimo's products like Stork™ and Bowers & Wilkins' headphones and car audio systems were recognized across different categories, highlighting their dedication to pushing design boundaries. The awards affirm Masimo's focus on delivering excellence in design and technology to enhance people's lives globally.

Masimo Stork™ and Bowers & Wilkins Garner Six Prestigious Accolades Across Multiple Categories

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) is proud to celebrate multiple wins across various categories at the prestigious iF DESIGN AWARDS 2024, showcasing its commitment to excellence in design and innovation throughout diverse industries.

Masimo Stork™ and Bowers & Wilkins Px8 (Photo: Business Wire)

With an impressive 11,000 submissions from 72 countries, the annual awards are organized by the esteemed iF International Forum Design GmbH in Hanover, Germany, and recognize outstanding achievements in design from around the world.

Under the Masimo umbrella, the following products have been honored with the coveted iF DESIGN AWARD seal:

• Masimo Stork™ – Baby Monitoring System (Baby/Kids category)
• Bowers & Wilkins Px7 S2e – Over-Ear Wireless Noise Canceling Headphones (Audio category)
• Bowers & Wilkins Px8 – Over-Ear Wireless Noise Canceling Headphones (Audio category)
• Bowers & Wilkins for Volvo EM90 – Car Audio System (Automotive category)
• Bowers & Wilkins for Aston Martin DB12 – Car Audio System (Automotive category)
• Bowers & Wilkins for BMW 5 Series – Car Audio System (Automotive category)

These wins underscore Masimo’s commitment to delivering excellence in design and innovation across a wide range of industries, from healthcare to consumer electronics. The recognition from iF DESIGN AWARDS reaffirms Masimo's dedication to pushing the boundaries of design and technology to improve the lives of people around the world.

Joe Kiani, Founder and CEO of Masimo, said, “We are honored to be recognized by iF Design. I’m especially proud that products from both our consumer health and our audio divisions, independently designed and addressing different needs, have been awarded simultaneously – a sign of our pursuit of excellence, innovation, and creativity across the board.”

The winners were selected by a distinguished jury comprising 132 independent experts from various fields, highlighting the global significance of these accolades.

Masimo remains committed to advancing healthcare technologies and enhancing consumer experiences through cutting-edge design and innovation. For more information about Masimo and its award-winning brands, please visit www.masimo.com.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.¹ Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,² improve CCHD screening in newborns³ and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.^4-7 Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,⁸ and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.⁹ In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVi^®), RPVi™ (rainbow^® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^®, Radius PPG^®, and Radius VSM™, portable devices like Rad-67^®, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^® and the Masimo W1^® medical watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris^® Gateway, iSirona™, Patient SafetyNet, Replica^®, Halo ION^®, UniView^®, UniView :60™, and Masimo SafetyNet^®. Its growing portfolio of health and wellness solutions includes Radius Tº^®, Masimo W1 Sport, and Masimo Stork™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

1. Published clinical studies on pulse oximetry and the benefits of Masimo SET^® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO₂ Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
8. Estimate: Masimo data on file.
9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements - Masimo

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

About the iF DESIGN AWARD

Since 1954, the iF DESIGN AWARD has been recognized as an arbiter of quality for excellent design. The iF Design brand is renowned worldwide for outstanding design services, and the iF DESIGN AWARD is one of the most important design prizes in the world. It honors design achievements in all disciplines: product, packaging, communication and service design, architecture and interior architecture as well as professional concept, user experience (UX) and user interface (UI). All award-winning entries are featured on ifdesign.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307205140/en/

Masimo

Matt Whewell

720-838-0691

Matt.whewell@masimo.com

Source: Masimo

FAQ

What awards did Masimo (MASI) and Bowers & Wilkins win at the iF DESIGN AWARDS 2024?

Masimo and Bowers & Wilkins received six prestigious accolades at the iF DESIGN AWARDS 2024 across various categories, including Baby Monitoring System, Over-Ear Wireless Noise Canceling Headphones, and Car Audio Systems.

Who organizes the iF DESIGN AWARDS 2024?

The iF DESIGN AWARDS 2024 are organized by the esteemed iF International Forum Design GmbH in Hanover, Germany.

What is the significance of the iF DESIGN AWARD seal?

The iF DESIGN AWARD seal recognizes outstanding achievements in design from around the world and highlights excellence in design and innovation.

What does Joe Kiani, Founder and CEO of Masimo, say about the awards?

Joe Kiani expressed pride in the recognition by iF Design, highlighting the simultaneous awards for products from different divisions as a testament to Masimo's pursuit of excellence, innovation, and creativity.

How were the winners selected for the iF DESIGN AWARDS?

The winners were chosen by a distinguished jury comprising 132 independent experts from various fields, showcasing the global significance of the accolades.